크리티컬 케어 진단 시장 : 제품별, 검사 유형별, 최종 용도별 - 세계 예측

Global Critical Care Diagnostics Market will witness 5.5% CAGR between 2024 and 2032, driven by the rising number of partnerships between leading companies. These collaborations are enhancing the development and distribution of advanced diagnostic technologies crucial for critical care settings. For instance, in June 2024, Radiometer and Etiometry entered into a new commercial partnership aimed at improving clinical decision-making and workflows in hospital environments. Under this collaboration, Etiometry's platform will be integrated with Radiometer's acute care diagnostic solutions, enabling critical care clinicians to access blood gas results, essential clinical data, additional physiological parameters, and AI-driven patient risk analytics all on a single screen.

These tools are essential for the accurate and timely diagnosis of complex conditions in critical care environments. Partnerships also facilitate the sharing of research and development costs, improving efficiency and bringing new products to market faster. As healthcare providers increasingly demand precise and reliable diagnostic solutions to manage critically ill patients, these strategic alliances are pivotal in meeting that need and driving market growth. Consequently, the Critical Care Diagnostics market is expanding rapidly, reflecting the importance of collaborative efforts in advancing healthcare technology.

The overall Critical Care Diagnostics Industry is classified based on the product, test type, end-use, and region.

Based on product, the critical care diagnostics market revenue from the cardiometabolic diagnostic kits segment will register a commendable CAGR from 2024 to 2032. These kits are crucial for assessing and managing conditions such as heart disease, diabetes, and metabolic syndrome, which are prevalent in critical care settings. By providing rapid and accurate diagnostic information, cardiometabolic kits enable healthcare providers to make informed decisions and tailor treatments to individual patient needs. The growing incidence of cardiometabolic disorders and the emphasis on early detection and personalized care are driving the adoption of these diagnostic tools. As a result, the market for critical care diagnostics is expanding, reflecting the need for advanced and precise diagnostic solutions.

In terms of test type, the hematology test segment will register appreciable growth from 2024 to 2032. Hematology tests, including complete blood counts and coagulation profiles, provide essential information on blood disorders, infection, and overall health status. In critical care settings, timely and accurate hematology results are vital for effective patient management and treatment decisions. The growing prevalence of hematological conditions and the need for rapid diagnostics in emergency and intensive care environments contribute to the rising demand. Consequently, advancements in hematology testing technologies are fueling market growth and improving patient outcomes.

Europe critical care diagnostics market will exhibit a modest CAGR from 2024 to 2032. European healthcare systems are increasingly adopting advanced diagnostic technologies to enhance the accuracy and efficiency of critical care management. This includes the integration of real-time monitoring systems, advanced imaging, and rapid diagnostic assays. The push for better patient care, coupled with regulatory support and investment in healthcare infrastructure, drives the growth of this market. Additionally, Europe's aging population and rising incidence of chronic conditions further contribute to the increasing demand for innovative critical care diagnostic solutions.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing geriatric population
    • 3.2.1.2 Rise in the prevalence of chronic diseases and lifestyle-related disorders
    • 3.2.1.3 Rising adoption of telehealth services and remote communications
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of molecular diagnostics tools
    • 3.2.2.2 Lack of skilled professionals
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Pricing analysis, 2023
  • 3.6.1 By region
  • 3.6.2 By key player
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Glucose diagnostic kits
• 5.3 Cardiometabolic diagnostic kits
• 5.4 Infectious disease testing kits
• 5.5 Hematology testing kits
• 5.6 Coagulation diagnostic kits
• 5.7 Cancer marker testing kits
• 5.8 Other products

Chapter 6 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Flow cytometry
• 6.3 Hematology test
• 6.4 Microbiology and infectious test
• 6.5 Coagulation test
• 6.6 Immunoprotein
• 6.7 Routine and special chemistry
• 6.8 Other test types

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Operation room
• 7.3 Intensive care unit
• 7.4 Emergency rooms
• 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Becton, Dickinson and Company
• 9.3 Bio-Rad Laboratories, Inc.
• 9.4 Danaher Corporation
• 9.5 F. Hoffmann-La Roche Ltd.
• 9.6 GE HealthCare Technologies, Inc.
• 9.7 Hologic, Inc.
• 9.8 Johnson & Johnson
• 9.9 Koninklijke Philips N.V.
• 9.10 Medtronic plc
• 9.11 Nihon Kohden Corporation
• 9.12 Nova Biomedical
• 9.13 Siemens Healthineers AG
• 9.14 Sysmex Corporation
• 9.15 Thermo Fisher Scientific Inc.